AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
4,739.50
+26.00 (+0.55%)
At close: 4:37PM GMT
Stock chart is not supported by your current browser
Previous close4,713.50
Open4,748.50
Bid4,730.00 x 6100
Ask4,900.00 x 13000
Day's range4,718.50 - 4,873.10
52-week range4,260.00 - 5,520.00
Volume2,115,987
Avg. volume2,329,685
Market cap60.021B
BetaN/A
PE ratio (TTM)20.00
EPS (TTM)237.00
Earnings date3 Feb 2016 - 8 Feb 2016
Forward dividend & yield2.53 (4.37%)
Ex-dividend date2017-08-10
1y target est73.80
  • Reuters - UK Focus15 hours ago

    AstraZeneca's immunotherapy drug wins key lung cancer approval

    AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration said late on Friday it granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.

  • Reutersyesterday

    U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

    Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute. In 2017, the drug was approved to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy.

  • Cyclicals, South Africa-exposed stocks help steady FTSE 100
    Reuters2 days ago

    Cyclicals, South Africa-exposed stocks help steady FTSE 100

    By Kit Rees LONDON (Reuters) - A rally in miners and stocks exposed to South Africa helped Britain's top share index close higher for a second day in a row on Thursday, stabilising after last week's hefty ...

  • Reuters - UK Focus2 days ago

    Cyclicals, South Africa-exposed stocks help steady FTSE 100

    A rally in miners and stocks exposed to South Africa helped Britain's top share index close higher for a second day in a row on Thursday, stabilising after last week's hefty sell-off. The blue chip FTSE ...

  • Reuters - UK Focus2 days ago

    Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

    Merck KGaA and Pfizer (NYSE: PFE - news) received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies. In the late stage trial of Bavencio, the drug could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

  • Reuters - UK Focus3 days ago

    Gains for South Africa-exposed stocks, cyclicals soothe FTSE 100

    The UK's top share index pushed higher on Thursday as a rally among stocks exposed to South Africa as well as banks and miners helped the FTSE in the early stages of a recovery. The blue chip FTSE 100 ...

  • Commodities help FTSE 100 outperform European stocks
    Reuters4 days ago

    Commodities help FTSE 100 outperform European stocks

    By Kit Rees and Helen Reid LONDON (Reuters) - A recovery among commodities stocks helped Britain's top share index outperform European peers on Tuesday, though it came under pressure from a firmer pound ...

  • Reuters - UK Focus4 days ago

    Commodities help FTSE 100 outperform European stocks

    A recovery among commodities stocks helped Britain's top share index outperform European peers on Tuesday, though it came under pressure from a firmer pound after some stronger-than-expected inflation ...

  • Reuters - UK Focus5 days ago

    FTSE 100 dips as strong pound dampens dollar-earners

    Britain's top share index came under pressure from a firmer pound on Tuesday following some stronger than expected inflation data, though a rise among mining groups stemmed losses. The blue chip FTSE 100 ...

  • Reuters - UK Focus6 days ago

    LIVE MARKETS-Pharma M&A, a sobering view from Moody's

    Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market ...

  • Reuters - UK Focus6 days ago

    Ex-divs to take 24.4 points off FTSE 100 on Feb.15

    The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, ...

  • Reuters9 days ago

    FTSE slides after BOE meeting as pound pops higher

    By Danilo Masoni and Kit Rees MILAN/LONDON (Reuters) - The UK's top share index fell on Thursday after the Bank of England raised the prospect of higher interest rates, sending the pound higher which weighed ...

  • Reuters - UK Focus9 days ago

    FTSE slides after BOE meeting as pound pops higher

    The UK's top share index fell on Thursday after the Bank of England raised the prospect of higher interest rates, sending the pound higher which weighed on big British overseas earners. The FTSE was closed ...

  • Reuters - UK Focus10 days ago

    FTSE dips ahead of BOE meeting but drugmakers give support

    The UK's top share index fell on Thursday before a Bank of England meeting widely expected to keep interest rates on hold, but gains among heavyweight drugmakers provided some support. GlaxoSmithKline (Other OTC: GLAXF - news) rose 2.6 percent after U.S. regulators delayed approval of a generic copy from Novartis (IOB: 0QLR.IL - news) of its blockbuster Advair lung drug and after the group took legal action against Gilead Sciences (NasdaqGS: GILD - news) over new HIV drug. The news helped build confidence after an upbeat results presentation by GlaxoSmithKline on Wednesday.

  • Reuters10 days ago

    GlaxoSmithKline sees light at end of Advair tunnel

    GlaxoSmithKline (GSK.L) sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year. Despite this threat and looming competition from a new Gilead Sciences (GILD.O) HIV drug, Chief Executive Emma Walmsley is more optimistic GSK will deliver on a promise of mid to high single digit earnings growth in the five years to 2020. Walmsley, who took over 10 months ago, is battling to rebuild GSK's drug pipeline by refocusing its research and appointing heavyweight outsiders, such as veteran Roche (ROG.S) scientist Hal Barron.

  • Reuters - UK Focus10 days ago

    GlaxoSmithKline sees light at end of Advair tunnel

    Despite this threat and looming competition from a new Gilead Sciences HIV drug, Chief Executive Emma Walmsley is more optimistic GSK will deliver on a promise of mid to high single digit earnings growth in the five years to 2020. Walmsley, who took over 10 months ago, is battling to rebuild GSK's drug pipeline by refocusing its research and appointing heavyweight outsiders, such as veteran Roche scientist Hal Barron. GSK is in the running to buy the Pfizer operation, according to sources familiar with the matter.

  • Reuters - UK Focus11 days ago

    Roche notches fresh win amid crowd of immunotherapy cocktails

    Roche's Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker's immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals. Tecentriq, paired with Roche's Avastin, cut risk of renal cell carcinoma advancing or death (PFS) by 26 percent in patients whose tumours expressed high levels of a protein believed to help avoid immune detection, the Basel-based drugmaker said on Tuesday. Roche said the overall survival benefit in its IMmotion 151 trial looked encouraging, but that data was not yet mature.

  • MarketWatch11 days ago

    Bristol-Myers touts lung cancer breakthrough, but critics cry foul

    The drugmaker says its findings advanced the scientific understanding of how to treat lung cancer, but critics say a major overhaul of the clinical trial design sullied the results.

  • Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint
    Zacks12 days ago

    Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint

    Losses on Wall Street and falling bond yields weighed on global markets this week.

  • AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
    Investor's Business Daily15 days ago

    AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro

    AstraZeneca's Lynparza is now king of the U.S. PARP inhibitor realm — beating out Tesaro — an analyst said Friday.

  • MarketWatch15 days ago

    FTSE 100 suffers worst week since April as bond yields spike

    U.K.’s benchmark stock index dropped for a fourth straight day on Friday, extending its weekly loss, after bond yields spiked following a better-than-expected reading on the U.S. labor market.

  • Reuters15 days ago

    Results, risk aversion drag FTSE 100 to worst week in nine months

    By Kit Rees LONDON (Reuters) - Britain's top share index sealed its worst week in nine months on Friday after results from BT were met with disappointment and commodities stocks tumbled amid a global equity ...

  • Reuters - UK Focus15 days ago

    Results, risk aversion drag FTSE 100 to worst week in nine months

    Britain's top share index sealed its worst week in nine months on Friday after results from BT were met with disappointment and commodities stocks tumbled amid a global equity market sell-off. The blue-chip ...

  • AstraZeneca's core numbers hide pharma firm's progress
    Sky News15 days ago

    AstraZeneca's core numbers hide pharma firm's progress

    Not for the first time results today from AstraZeneca (Swiss: AZN.SW - news) (AZ (Stuttgart: A1131G - news) ), the UK's second-largest drug maker, are something of a curate's egg. Pascal Soriot, chief executive, had previously promised that 2017 would be the year that the Cambridge-based company's sales would start to grow again.

  • Reuters15 days ago

    AstraZeneca flags return to drug growth in 2018, China shines

    AstraZeneca (AZN.L) expects a return to drug sales growth in 2018 as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit this year. AstraZeneca has suffered the industry's biggest patent cliff since 2012, wiping out more than half of its sales, but Chief Executive Pascal Soriot said it was turning a corner and spending as a proportion of sales would reduce by 2019-20. After a 5 percent fall in 2017, the group expects drug sales this year to grow at a low single-figure percentage rate, driven by new treatments for cancer, in particular, and buoyed by 20 percent-plus sales growth in China.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes